Public Health

SHA Changes Cancer Treatment Approvals, Maintains KES 800,000 Benefit

SHA says new cancer treatment approval and pricing changes aim to standardise costs and protect patients, while the KES 800,000 oncology benefit remains unchanged.

The Social Health Authority (SHA) headquarters in Nairobi, reflecting Kenya’s ongoing health financing reforms aimed at expanding access to healthcare, improving financial protection and making essential treatment more affordable for patients, including those seeking cancer care.
The Social Health Authority (SHA) headquarters in Nairobi, reflecting Kenya’s ongoing health financing reforms aimed at expanding access to healthcare, improving financial protection and making essential treatment more affordable for patients, including those seeking cancer care.

The decision brief

What is changing?

SHA has revised cancer treatment approval and pricing arrangements to align care with national cancer guidelines, standardise charges and protect patients from unnecessary costs. The overall KES 800,000 oncology benefit remains unchanged, split between KES 400,000 under SHIF and KES 400,000 under ECCIF.

What is coming next?

Hospitals and providers are expected to apply the revised approval process and approved tariffs. Patients should check their eligibility, treatment approvals and any costs outside the covered package as the arrangements are implemented.

What does it mean?

Standardised approvals and prices could reduce variation in what patients are charged and help prevent benefit limits from being exhausted prematurely. The benefit is not blanket coverage: treatment remains subject to eligibility, guidelines and the approved package.

What solutions are available?

Apply national cancer treatment guidelines and approved tariffs consistently; explain uncovered costs to patients before services are provided; and use SHA's official customer-service channels to resolve questions or disputed charges.

Who is offering them?

The Social Health Authority (SHA), working within the Ministry of Health framework and with the National Cancer Control Programme and consulted oncology, pharmacy, nursing and healthcare-provider stakeholders.

Nairobi, Kenya — 20 November 2026 — The Social Health Authority (SHA) has introduced changes to cancer treatment approvals and pricing, saying the reforms are intended to improve access to care, standardise costs and protect patients from unnecessary out-of-pocket expenses. The Authority says the approved cancer treatment benefit of KES 800,000 per patient remains unchanged.

In a public notice issued on Friday, SHA said the oncology benefit comprises KES 400,000 under the Social Health Insurance Fund (SHIF) and a further KES 400,000 under the Emergency, Chronic and Critical Illness Fund (ECCIF). The allocation is provided for under Legal Notice No. 56 of 2025 and Legal Notice No. 78 of 2026.

The changes are intended to align treatment with the National Cancer Treatment Guidelines and standardise the pricing and reimbursement of cancer medicines and services. SHA said differing charges for similar treatments had previously contributed to cost variations and, in some cases, patients exhausting their cover before completing treatment.

The revised approach is expected to apply approved treatment guidelines and tariffs more consistently. SHA said the review was led through consultations by the Ministry of Health’s National Cancer Control Programme, involving oncologists, pharmacists, nurses, public and private healthcare providers and professional associations.

What patients should know

SHA says access to the oncology benefit remains subject to treatment guidelines, approved tariffs and eligibility requirements. Services outside the approved benefits package are not automatically covered.

Hospitals are required to explain any additional costs for services not covered by SHA before providing them. The Authority also says patients should not be charged again for services that are already covered and paid for under the benefit package. Any extra charges should be clearly explained and justified within the applicable rules.

The notice comes amid public concern and reports from cancer patients about treatment approvals, limits and additional payments. The distinction between the unchanged overall benefit and how specific medicines, tests or services are approved and reimbursed will be important for patients and providers as the new arrangements take effect.

Patients facing disputed charges or having questions about their cancer treatment coverage are encouraged to contact SHA through its official customer service channels.

Sources

Health Signal Africa will continue tracking how the approval changes affect access to cancer treatment, patient costs and continuity of care.

Discussion

Leave a Reply

Your email address will not be published. Required fields are marked *